Mei Sakuma et al. suggested that the change of CD45RA − CD27 + CD127 + central memory T cells frequency during nivolumab treatment might be a biomarker for predicting its therapeutic effect on esophageal squamous cell carcinoma patients [26]. This evidence concerns the gene IL7R and esophageal squamous cell carcinoma.